trending Market Intelligence /marketintelligence/en/news-insights/trending/fQYLLlURBJm2SujCVI8C6g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

AstraZeneca's Qternmet XR approved by FDA as add-on therapy for type 2 diabetes

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


AstraZeneca's Qternmet XR approved by FDA as add-on therapy for type 2 diabetes

AstraZeneca PLC's medicine Qternmet XR was approved by the U.S. Food and Drug Administration as an add-on therapy for adults with type 2 diabetes.

The U.K.-based pharmaceutical giant's extended-release tablet Qternmet XR is a combination of its medicines Forxiga, also known as dapagliflozin; Onglyza, or saxagliptin; and metformin hydrochloride.

Qternmet XR was approved as an adjunct treatment to diet and exercise to improve glucose control in patients with type 2 diabetes.

The approval was based on positive data from two phase 3 trials, which showed that the drug helped reduce blood glucose levels.